

Table 1. Consensus survey on spinal muscular atrophy (SMA) treatment in Singapore (March to April 2023).

Regarding symptomatic treatment*	Agree, no. of votes (%)
Factors influencing decision to start treatment	
Type of SMA/SMN2 copy number	14 (100)
Requirement for ventilatory support	13 (92.9)
Stage of disease	13 (92.9)
Family support	11 (78.6)
Compliance to multidisciplinary care	11 (78.6)
Requirement for assisted feeding	8 (57.1)
Financial status	8 (57.1)
Comorbidities, e.g. scoliosis	8 (57.1)
Factors influencing decision to exclude from treatment	
Previous hypoxic-ischaemic injury/cognitive impairment	11 (78.6)
Poor family compliance	10 (71.4)
Permanent ventilation/tracheostomy dependence	8 (57.1)
Cardiomyopathy	6 (42.9)
Chronic diseases	6 (42.9)
Psychiatric illness	5 (35.7)
Liver dysfunction	3 (21.4)
Swallowing dysfunction requiring feeding tube >1 month	1 (7.1)
Scoliosis	1 (7.1)
Factors influencing decision to stop treatment	
Poor compliance	13 (92.9)
Unacceptable side effects of drugs	12 (85.7)
Progression to ventilatory support	11 (78.6)
Persistent decline in motor function scores (>10% drop across 3 visits)	8 (57.1)
Increase in ventilatory support for >3 months	6 (42.9)
Progression to NGT feeding/gastrostomy	5 (35.7)
Frequent respiratory infections requiring hospitalisations ≥3x/year	4 (28.6)
No improvements in motor function scores	4 (28.6)
Loss of patient-reported functional skills	4 (28.6)
Progressive scoliosis (Cobbs angle >40°)	2 (14.3)
Clinical worsening of swallowing function	1 (7.1)
Drop in weight across ≥2 centiles	1 (7.1)
Reasonable minimum treatment period for efficacy assessment	
6 months	2 (14.3)
9 months	1 (7.1)
12 months	10 (71.4)
2 years	1 (7.1)
Regarding presymptomatic treatment	Agree, no. of votes (%)
I support presymptomatic treatment over best supportive care	13 (92.9)
First-line treatment	
Nusinersen	1 (7.1)
OAV	10 (71.4)
Risdiplam	2 (14.3)
I support newborn screening	
Opt-out	8 (57.1)
Opt-in	6 (42.9)
I support treatment for these patients:	
1 SMN2 copies	12 (85.7)
2 SMN2 copies	14 (100)
3 SMN2 copies	13 (92.9)
4 SMN2 copies	3 (21.4)
>4 SMN2 copies	1 (7.1)
Funding should be prioritised for:	
Carrier screening	3 (21.4)
Preconception screening	1 (7.1)
Newborn screening	10 (71.4)

NGT: nasogastric tube; OAV: onasemnogene abeparvovec

* Case scenarios to investigate treatment threshold in separate unpublished appendix (available upon reasonable request from the corresponding author).